|Day Low/High||2.74 / 2.82|
|52 Wk Low/High||2.66 / 4.60|
Investors in Amarin Corp plc saw new options become available this week, for the December 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Over 97% of Final Patient Visits in REDUCE-IT Completed or Scheduled for Near-Term Completion
On Track to Report REDUCE-IT Results Before the End of Q3 2018
Increasing Awareness of Triglycerides and a Call to Action for People to Talk to Their Doctors, Nurses & Pharmacists About Their Triglyceride Levels
Lebanon Approves Vascepa for Sale, First in Series of Anticipated Approvals
Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.
'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.
Jim Cramer spotlights Twilio, Apache, Tellurian, Atara Biotherapeutics, Amarin, Dynavax Technologies
Jim Cramer says this is a market that triumphs over the gloom by simply taking stock of the good and running with it. He's got your game plan for next week.
Study Results Anticipated to be Released by End of Q3 2018
Presentations to Include Additional Real-World Data, Clinical and Cost Analyses of Patient Outcomes From Managed Care Databases
Investors in Amarin Corp plc saw new options begin trading this week, for the September 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
On Track for Patient Final Study Visits to Commence in March 2018
On-Track to Report Clinical Results for this Potential Landmark Study Before the End of Q3 2018
High Triglyceride Levels Associated with 30% Increased Risk of Myocardial Infarction & Coronary Revascularization and 13% Overall Increase in Major Adverse Cardiovascular Events
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.